An integrated analysis of single-cell and bulk transcriptomics reveals EFNA1 as a novel prognostic biomarker for cervical cancer

Hum Cell. 2022 Mar;35(2):705-720. doi: 10.1007/s13577-022-00679-4. Epub 2022 Jan 24.


Cervical cancer is a serious threat to women's health and lives worldwide. The recovery and survival of cervical cancer can be improved by customizing therapy strategies based on individual-specific gene expression patterns. EFNA1 was reported to be dysregulated in many cancers and associated with their overall survivals, but its prognostic value in cervical cancer is still unclear. In this study, we performed analyses on the single-cell and bulk RNA sequencing data to study the role of EFNA1 in cervical cancer. EFNA1 was found to be significantly upregulated in cervical cancer tissue, especially the cancer cell subgroup within tumors, which was verified by immunohistochemistry. Through Cox regressions, we found that high EFNA1 expression is an independent risk factor for cervical cancer. Nomogram analysis indicated that EFNA1 could be a predicting factor for the survival probabilities of cervical cancer. Gene ontology and pathway analyses showed that EFNA1 was involved in many tumorigenesis pathways, protein, and virus productions. These findings suggested that EFNA1 could be a prognostic biomarker and potential therapeutic target for cervical cancer.

Keywords: Cervical cancer; EFNA1; Prognosis; RNA-seq; scRNA-seq.

MeSH terms

  • Biomarkers
  • Biomarkers, Tumor / genetics
  • Ephrin-A1* / genetics
  • Ephrin-A1* / metabolism
  • Female
  • Humans
  • Prognosis
  • Transcriptome / genetics
  • Uterine Cervical Neoplasms* / diagnosis
  • Uterine Cervical Neoplasms* / genetics


  • Biomarkers
  • Biomarkers, Tumor
  • EFNA1 protein, human
  • Ephrin-A1